Descrizione del progetto
Identificare nuovi meccanismi per il trattamento del dolore osseo
Il dolore muscoloscheletrico derivante da patologie come l’artrite e i tumori legati alle ossa è causa di un notevole onere per la società. Le attuali opzioni terapeutiche, tra cui gli oppioidi, i farmaci antinfiammatori non steroidei e i farmaci modificanti la malattia, spesso non riescono a fornire un adeguato sollievo dal dolore. Il progetto BonePainIII, finanziato dal programma di azioni Marie Skłodowska-Curie, affronterà questa sfida sviluppando programmi di formazione completi rivolti ai ricercatori con il triplice obiettivo di migliorare la traduzione clinica della ricerca sul dolore osseo e la scoperta di farmaci, individuare nuovi meccanismi e bersagli terapeutici e valutare l’efficacia di terapie in fase clinica. Per raggiungere queste finalità, il progetto utilizzerà modelli umanizzati di organi su chip, modelli murini e biopsie di pazienti al fine di raccogliere dati clinicamente rilevanti. Inoltre, l’iniziativa offrirà agli studenti una formazione interdisciplinare innovativa che abbraccia diversi settori.
Obiettivo
Musculoskeletal pain from diseases such as arthritis and cancer in the bone affects the quality of life of millions and is a major societal burden. The current treatment options are opioids, non-steroid anti-inflammatory drugs and disease modifying drugs; however, these are often insufficient in providing an adequate pain relief. This is due to dose limiting side effects, the risk of misuse and addiction (opioids) and lack of efficacy. Thus, there is a strong unmet medical need. Drug development in pain has been hampered by a poor translation of preclinical data to the clinic and a lack of understanding of the underlying mechanisms. Therefore, in this project 4 academic beneficiaries, 3 industrial beneficiaries, 2 industrial partners and 3 academic partners join forces to create an outstanding and integrated training program for early stages researchers to increase the clinical translation of bone pain research and drug discovery and to provide novel mechanistic insight and potential therapeutic targets. We will develop fully humanized organ-on-a chip models of the painful bone disease microenvironment and we will use humanized mouse models, and tissue and liquid biopsies from patients to obtain clinically relevant data. Moreover, we will identify new disease mechanisms and potential treatment targets and explore the efficacy of clinical stage therapeutics in mouse models of the painful skeletal diseases osteoarthritis, rheumatoid arthritis, cancer in the bone and the rare bone disease, fibrous dysplasia. In an extensive training effort covering both specific research skills and transferable skills, the students will obtain an interdisciplinary, state-of-the-art and innovative training from the participants across sectors. The students will benefit from secondments with industrial partners and with some of the foremost pain researchers in Europe.
Campo scientifico
Programma(i)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Meccanismo di finanziamento
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinatore
1165 Kobenhavn
Danimarca